Literature DB >> 9144471

Enhanced CTL responses mediated by plasmid DNA immunogens encoding costimulatory molecules and cytokines.

A Iwasaki1, B J Stiernholm, A K Chan, N L Berinstein, B H Barber.   

Abstract

In the course of examining epitope-specific CTL responses to intramuscular plasmid DNA immunization with influenza nucleoprotein (NP)-expressing vectors, a nonimmunogenic mutant NP (NP(o)) was identified. The coding region of NP(o) differed from the wild-type A/PR/8/34 NP sequence (designated NP(v)) by three amino acid alterations in the carboxyl-terminal portion of the molecule remote from the H-2K(d) epitope (147-155) being monitored. Correction of these mutations restored the immunogenicity of the native sequence, indicating that sequence alterations remote from the CTL epitope in question can profoundly influence its immunogenicity. In an effort to identify general, nonstructural means of enhancing the CTL response to weak plasmid DNA immunogens, vectors were constructed expressing NP(o) in tandem with the costimulatory molecules B7-1 or B7-2. Co-linear expression of NP(o) with B7-2, but not B7-1, significantly increased the NP epitope-specific CTL response. In addition, coinjection of these NP(o) plasmids with granulocyte-macrophage CSF- and/or IL-12-expressing vectors also restored near native NP-specific CTL responses. Thus, the coexpression of certain costimulatory molecules and/or cytokines, in concert with a non-self gene delivered as an intramuscular plasmid DNA immunogen, can significantly enhance Ag-specific CTL responses.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9144471

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  52 in total

1.  Restricting expression prolongs expression of foreign genes introduced into animals by retroviruses.

Authors:  V B Pinto; S Prasad; J Yewdell; J Bennink; S H Hughes
Journal:  J Virol       Date:  2000-11       Impact factor: 5.103

Review 2.  Nucleic acid vaccines: tasks and tactics.

Authors:  B S McKenzie; A J Corbett; J L Brady; C M Dyer; R A Strugnell; S J Kent; D R Kramer; J S Boyle; A M Lew
Journal:  Immunol Res       Date:  2001       Impact factor: 2.829

3.  Enhancing B- and T-cell immune response to a hepatitis C virus E2 DNA vaccine by intramuscular electrical gene transfer.

Authors:  S Zucchelli; S Capone; E Fattori; A Folgori; A Di Marco; D Casimiro; A J Simon; R Laufer; N La Monica; R Cortese; A Nicosia
Journal:  J Virol       Date:  2000-12       Impact factor: 5.103

4.  Subsets of memory cytotoxic T lymphocytes elicited by vaccination influence the efficiency of secondary expansion in vivo.

Authors:  Michael S Seaman; Fred W Peyerl; Shawn S Jackson; Michelle A Lifton; Darci A Gorgone; Jörn E Schmitz; Norman L Letvin
Journal:  J Virol       Date:  2004-01       Impact factor: 5.103

5.  Modulation of antigen-specific humoral responses in rhesus macaques by using cytokine cDNAs as DNA vaccine adjuvants.

Authors:  J J Kim; J S Yang; T C VanCott; D J Lee; K H Manson; M S Wyand; J D Boyer; K E Ugen; D B Weiner
Journal:  J Virol       Date:  2000-04       Impact factor: 5.103

6.  The efficacy of DNA vaccination is enhanced in mice by targeting the encoded protein to dendritic cells.

Authors:  Godwin Nchinda; Janelle Kuroiwa; Margarita Oks; Christine Trumpfheller; Chae Gyu Park; Yaoxing Huang; Drew Hannaman; Sarah J Schlesinger; Olga Mizenina; Michel C Nussenzweig; Klaus Uberla; Ralph M Steinman
Journal:  J Clin Invest       Date:  2008-04       Impact factor: 14.808

7.  Magnitude and frequency of cytotoxic T-lymphocyte responses: identification of immunodominant regions of human immunodeficiency virus type 1 subtype C.

Authors:  V Novitsky; H Cao; N Rybak; P Gilbert; M F McLane; S Gaolekwe; T Peter; I Thior; T Ndung'u; R Marlink; T H Lee; M Essex
Journal:  J Virol       Date:  2002-10       Impact factor: 5.103

8.  Immunization with a vaccine that combines the expression of MUC1 and B7 co-stimulatory molecules prolongs the survival of mice and delays the appearance of mouse mammary tumors.

Authors:  Vitaly Vasilevko; Anahit Ghochikyan; Nadya Sadzikava; Irina Petrushina; Mike Tran; Edward P Cohen; Patrick J Kesslak; David H Cribbs; Garth L Nicolson; Michael G Agadjanyan
Journal:  Clin Exp Metastasis       Date:  2003       Impact factor: 5.150

9.  Toxoplasma gondii: immune response and protective efficacy induced by ROP16/GRA7 multicomponent DNA vaccine with a genetic adjuvant B7-2.

Authors:  Qi Liu; Fuwu Wang; Guan Wang; Qunli Zhao; Juan Min; Shuai Wang; Hua Cong; Ying Li; Shenyi He; Huaiyu Zhou
Journal:  Hum Vaccin Immunother       Date:  2013-10-07       Impact factor: 3.452

10.  CD40 ligand/trimer DNA enhances both humoral and cellular immune responses and induces protective immunity to infectious and tumor challenge.

Authors:  S Gurunathan; K R Irvine; C Y Wu; J I Cohen; E Thomas; C Prussin; N P Restifo; R A Seder
Journal:  J Immunol       Date:  1998-11-01       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.